REAL-WORLD EVIDENCE TO SUPPORT PAYER/HTA DECISIONS ABOUT HIGHLY INNOVATIVE TECHNOLOGIES IN THE EU - ACTIONS FOR STAKEHOLDERS

Karen M. Facey BSc PhD (Statistics) (corresponding)
Senior Research Fellow, Usher Institute, University of Edinburgh, Nine Bioquarter, 9 Little France Road, Edinburgh, EH16 4UX. UK
Email: karen.facey@ed.ac.uk
Phone: +44 (0)789 414 3931

Piia Rannanheimo, MSc (Pharm.)
Pharmacoeconomist, Finnish Medicines Agency, P.O.Box 55, FI-00034 Finland.
Email: piia.rannanheimo@fimea.fi

Laura Batchelor MA (Languages)
Partner, FIPRA, Rue de la Loi 227, 1040 Brussels, Belgium.
Email: laura.batchelor@fipra.com

Marine Borchardt BA LLM MA (Law and Politics)
Senior Account Executive, FIPRA, Rue de la Loi 227, 1040 Brussels, Belgium.
Email: marine.borchardt@fipra.com

Jo De Cock MA (Law, Criminology)
CEO, National Institute for Health and Disability Insurance (RIZIV/INAMI), Tervurenlaan 211, 1150 Brussels, Belgium.
Email: jo.decock@riziv-inami.fgov.be

ABSTRACT

Objectives
There are divergent views on the potential of real-world data (RWD) to inform decisions made by regulators, HTA bodies, Payers, clinicians and patients. This RWE4Decisions initiative explored the particularly challenging setting of highly innovative technologies, which require Payers/HTAs to make decisions on a small evidence base with major uncertainties. The aim was to go beyond strategic intent to consider actions that each stakeholder could take to improve use of RWD in this setting.

Results
Case studies of recent Payer/HTA assessments about highly innovative technologies were considered in light of recent international initiatives about RWD. This showed a lack of clarity about the Payer/HTA questions that could be answered by RWD and how the quality of real-world evidence (RWE) could be assessed. All stakeholders worked together to create a vision whereby stakeholders agree what RWD can be collected for highly innovative technologies based on principles of collaboration and transparency. For each stakeholder group, recommended actions to support the generation, analysis and interpretation of RWD to inform decision-making were developed. For HTA bodies, this includes cross border HTA/regulatory collaboration to agree RWD requirements over the technology life cycle to inform initial recommendations and reassessment, data analytics methods development for HTA and promotion of transparency in RWE studies.
**Recommendations**

Stakeholders need to collaborate on demonstration projects to consider how RWE can be developed to inform healthcare decisions and contribute to a learning network that can develop systems to support a learning health system and improve patient outcomes through best use of RWD.

**KEYWORDS**

Decision-making, Reimbursement mechanisms, Stakeholder participation, Real-world data, Real-world evidence

**ACKNOWLEDGEMENTS**

The following individuals were members of the Review Group that contributed to the exploration of the issues and development of the stakeholder actions presented in this paper: Lieven Annemans, University of Ghent; Simone Boselli, EURORDIS; Simon Butler, Gilead Sciences; Antonella Cardone, European Cancer Patient Coalition; Marc van de Casteele, INAMI; Ivana Cattaneo, Novartis; Mercedes Echauri, Takeda; Marie-Hélène Fandel, Amgen; Ansgar Hebborn, Hoffman La Roche; Frank Hulstaert, Belgian Health Care Knowledge Centre; Kaisa Immonen, European Patients’ Forum; Xavier Kurz, EMA; Denis Lacombe, European Organisation for Research and Treatment of Cancer; Amr Makady, formerly Dutch National Healthcare Institute (ZIN); Alexander Natz, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE); Ulla Närhi, Finnish Permanent Representation to the EU; Patrick Neven, UZ Leuven; Aisling O’Leary, National Centre for Pharmacoeconomics (Ireland); Delphine Roulland, formerly EUCOPE; Ad Schuurman, European Medicines Agency; Jennifer Shum, AstraZeneca; Timon Sibma, ZIN; Chris Sotirelis, EMA Patient Expert; Bjørn Oddvar Strøm, Norwegian Medicines Agency; Lonneke Timmers, ZIN; Sheela Upadhyaya, NICE; Entela Xoxi, Catholic University of Rome.

**SOURCE OF FUNDING**

This work was financially supported by EUCOPE, Amgen, AstraZeneca, Gilead Sciences, Roche, Takeda and Novartis which covered the costs of the multi-stakeholder meetings, the work of FIPRA and KF for workshop facilitation. Some workshop participants received travel expenses. KF undertook other elements, including all consultation and writing activities as part of her work in the EC H2020 IMPACT HTA project (grant number RE8213). PR and JdeC undertook all work independently under the auspices of their employers.
MAIN PAPER

Background

Highly innovative technologies (such as immuno-, cell and gene therapies that use novel molecular biology to target the underlying cause of a disease) aim to deliver transformative patient benefit. Where large potential benefit is expected in areas of high unmet medical need (such as in rare diseases), regulators have developed expedited pathways. Regulatory approval based on interim analyses of short-term endpoints and early data cut-offs is common, as is the use of uncontrolled trials. This means that some health technologies enter the market with a limited evidence base to demonstrate clinical effectiveness.

There is substantial pressure for Payers (or HTA bodies) to make (or inform) pricing and reimbursement decisions about these technologies at the point of market launch. However, uncertainties exist about the population to be treated, natural history of disease, size and durability of clinical effects compared to treatment alternatives, safety, cost effectiveness and budget impact. As these highly innovative technologies often have a high price due to the complexity of development and purported high patient benefit, decisions about their value are challenging.

Although less than twenty cell and gene therapies had received regulatory approval by the end of 2019 in the EU, in early 2020 there were 1,000 clinical trials underway in over 400 companies, so Payers/HTA need to quickly find ways to evolve their decision-making processes to help resolve uncertainties and mitigate risks. One option is to consider a longitudinal approach to evidence generation with collection of real-world data (RWD) over the life cycle of the technology.

The potential to use RWD to make decisions about highly innovative technologies links into the major scientific and technological advancements in digital health. Numerous national and transnational collaborations are expected to contribute to improvements in quality, coverage and access to RWD and have the potential to create learning health systems that will improve patient outcomes. The health technology industry, health systems, clinicians, patients and methodologists are working to improve use of real-world/big data in the healthcare sector. However, views differ on how RWD can be used and the potential to generate robust reliable real-world evidence (RWE) to inform major decisions.

Regulators have used RWE for many years for pharmacovigilance and have recently developed frameworks for use of RWE in wider regulatory contexts, but continue to state that evidence from randomised-controlled trials (RCT) remains the best available standard for demonstration of efficacy and such data should be seen as complementary to RCT evidence. Medical and regulatory leaders across the EU have highlighted that the evidence requirements for regulatory decisions are not the same. Acceptability is influenced by the question being asked, the level of risk and other considerations such as the ability to capture other data, availability of other treatments and unmet medical need.

Such contextual considerations also influence Payer/HTA views on the persuasiveness of RWE. In the US, it has been stated that demonstration of superiority, expansion of use, contradiction with RCT results or major change in clinical practice will all require a "high evidence bar". Whereas assertion of equivalent effectiveness and lower cost, a new safety signal and complementing RCT data to fill gaps may all be "low evidence bar" situations. Both regulators and Payers/HTA agree that acceptability of RWE is dependent on data and methodological processes to control for bias and confounding.

In 2017, the CEO (de Cock) of the National Institute for Health and Disability Insurance (INAMI/RIZIV) initiated a series of multi-stakeholder initiatives to explore whether robust RWE could be obtained to close evidentiary gaps in Payer/HTA
decisions, particularly in relation to rare disease treatments. The resulting reports included principles for use of RWD over the entire technology life cycle (3) and for Outcomes-Based Managed Entry Agreements (OB-MEA) (18). Annemans and Makady (19) reported on the TRUST4RD initiative, producing a Tool for Reducing Uncertainties in the evidence generation for Specialised Treatments for Rare Diseases. It included a taxonomy of evidence/uncertainties that arise with rare disease treatments to support iterative multi-stakeholder dialogues and recognized that RWE may be able to resolve uncertainties about natural history, the interaction between the technology and the disease (including long-term treatment effects), and uncertainties related to the healthcare ecosystem.

Although these were multi-stakeholder initiatives with broad buy-in, there was still a lack of uptake and little advancement in use of RWD for decision-making. Hence it was decided to consider how these three initiatives and other ongoing RWD policy activities could be applied to the challenges associated with Payer/HTA decisions for highly innovative treatments, which was an issue that loomed large in 2019.

This initiative, RWE4Decisions was commissioned by INAMI/RIZIV to explore with all stakeholders the potential use of RWD in this specific case of making Payer/HTA decisions about highly innovative technologies and agree clear actions. It excluded consideration of underpinning issues about data sources, methodologies, governance, analytics and infrastructure that were being addressed by others (6, 20).

This paper explains the methods used and the resulting vision and key principles. It outlines key stakeholder roles in relation to RWD and proposes actions for each stakeholder group to test the use of RWD to inform Payer/HTA decisions about highly innovative technologies. Finally, consideration is given to how a multi-stakeholder learning network for RWE can be established to align work with other initiatives, share best practices and develop guidance that will ultimately lead to optimization of treatment and outcomes through best use of RWD.

Methods

All work was undertaken according to the ‘Bad Gastein’ principle of equal representation of all stakeholders from the fields of public health and healthcare (21). Representatives from HTA bodies, payers, regulators, government bodies, clinical research organizations, pharmaceutical industry, patient groups and academia participated in meetings and email consultations (the Review Group) and a sub-group involving all stakeholders brainstormed ideas arising between each step via teleconference (the Task Force). This work linked into the EU Finnish Presidency program in 2019 on the “economy of well-being” that included discussion about using RWD for evaluation of the value of pharmaceuticals, and included consultation as outlined below.

A mixed-methods approach was used that explored recent policy proposals about use of RWD applied to the specific context of Payer/HTA decisions about highly innovative technologies and developed feasible actions that were implementable by each stakeholder group. Workshops, teleconference and email consultations were used over several months as follows:

- Presentations from the Finnish Health/Pharmaceutical Attache to the EU, a payer collaborative, HTA bodies and a European clinical network explored the challenges with use of RWE to resolve the Payer/HTA uncertainties emerging with highly innovative technologies. A roundtable discussion drawing in European patient groups and industry representatives discussed what practical steps could be taken.
• Desk top research – Selected policy documents from the EU and USA about the use of RWD in regulatory and HTA decision-making published from January 2018-April 2019 were reviewed and discussed to avoid “reinventing the wheel”.
• Case studies – Members of the initiative were asked to put forward case studies of marketed highly innovative technologies where RWE was pivotal to reimbursement decisions or where challenges in RWD collection remained. This resulted in one case study from HTA (relating to nusinersen), one from a Payer (relating to tisagenleucel) and two confidential topics from industry.
• Development of stakeholder actions – After the case study workshop, each individual wrote down actions they felt were needed by each stakeholder to make consistent use of RWD in Payer/HTA decisions become a reality. Actions were discussed on the day, then amalgamated and refined by the Taskforce and their networks over several months, including a presentation to the EU Chief Pharmaceutical Officers.
• Version 1 of the stakeholder roles and actions were issued publicly for 3 months consultation with a specific request to encourage European stakeholder groups to respond. The actions were also presented at international meetings for feedback. Detailed feedback was received from eleven expert groups and major revisions were made to the actions. The revised actions were then reviewed by the Task Force and finalized by the authors.

Meetings were chaired by de Cock and an ex EU parliamentarian. Facey undertook the desktop research, facilitated the workshop and helped prepare materials with Batchelor and Borchardt who organised all meetings. Rannanheimo was the key link to the Finnish EU Presidency and provided substantial input to the redrafting of the recommended actions and learning network proposals.

Results

The Potential for Use of RWD in Decision-Making in the EU

The initial stakeholder presentations and discussions with stakeholders identified that EU Member States (MS) differ markedly in their digital health capabilities. Some have excellent electronic health (and other government) records that can be linked via a unique patient identifier (Finland, Scotland, Norway, Sweden, France), but analyses can be cumbersome and key information such as diagnosis may not be recorded on prescriptions. Other MS have developed bespoke registries to monitor appropriate utilization of new pharmaceuticals and enable OB-MEA (Italy, Portugal). Hence the landscape for RWD collection is disparate across the EU and the infrastructure and governance frameworks to enable data sharing across EU MS do not yet exist. Initiatives are underway to address these concerns (13, 8) at an international policy level, but these are complex and will take time. So, this work focused on the specific issue of making pricing and reimbursement decisions about highly innovative technologies, seeking to develop feasible actions for each stakeholder at a national or transnational level that could be enacted now and in the near future.

The desktop research identified recent initiatives to support use of RWE in healthcare decision-making. These all highlighted the need for developments in data governance to enable appropriate data sharing according to data protection legislation and robust methodological approaches to address biases. Key elements about the potential use of RWD were interpreted for the Payer/HTA decision-making context as shown in Table 1.
Table 1. Stakeholder Views on RWE in Decision-Making

| Regulator (European Medicines Agency - EMA) | Potential uses of RWE | What do we need? | Initiatives |
|---------------------------------------------|----------------------|-----------------|-------------|
|                                             | Novel insights on use and performance of medicines, complementing RCT evidence | Evidentiary standards for RWE that take account of context | **Registries initiative** to promote dialogue about use of disease registries for regulatory purposes and EMA qualification |
|                                             | Epidemiology         | • Adequate range of characteristics of population covered | **https://www.ema.europa.eu/en/human-regulatory/post-authorisation/patient-registries** |
|                                             | Contextualize efficacy | • Good quality RWD sources with data that are quality assured | |
|                                             | Patient-reported outcomes | • Agreement on common core data elements | **OPTIMAL framework:** |
|                                             | Pharmacovigilance     | • Validity and consistency of analyses across sources | **Operational (data infrastructure)** |
|                                             |                      |                 | - feasibility |
|                                             |                      |                 | - governance |
|                                             |                      |                 | - sustainability |
|                                             |                      |                 | **Technical** |
|                                             |                      |                 | - extent and completeness of data |
|                                             |                      |                 | - appropriate terminology and data formats |
|                                             |                      |                 | - potential for data linkage |
|                                             |                      |                 | - consistent, accurate and timely data collection and management |
|                                             |                      |                 | **Methodological** |
|                                             |                      |                 | - understanding of data source |
|                                             |                      |                 | - evaluation of variability in multi-data source studies |
|                                             |                      |                 | - adequate data collection and analysis on potential confounders and effect modifiers |
|                                             |                      |                 | **https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617710/** |
|                                             |                      |                 | **HMA-EMA joint Big Data Task Force** informing EU strategy to 2025 to seize the opportunity for data-driven, evidence-based, robust decision-making. |
|                                             |                      |                 | **https://www.ema.europa.eu/en/documents/other/hma-ema-joint-big-data-taskforce-phase-ii-report-evolving-data-driven-regulation_en.pdf** |
| Potential uses of RWE | What do we need? | Initiatives |
|----------------------|------------------|-------------|
| **HTA** | Resolution of uncertainties in determination of value | Agreement across HTA programmes and HTA bodies about the potential for use of RWE, development of analytics expertise to support RWE critical assessment and cross-organisational collaboration to | **EUnetHTA REQUEST tool** evaluates data quality and usability of clinical registries for HTA purposes [https://eunethta.eu/request-tool-and-its-vision-paper/](https://eunethta.eu/request-tool-and-its-vision-paper/)  
**EUnetHTA Post-Licensing Evidence Generation pilots** [https://eunethta.eu/ja3-archive/work-package-5-life-cycle-approach-to-improve-evidence-generation/](https://eunethta.eu/ja3-archive/work-package-5-life-cycle-approach-to-improve-evidence-generation/)  
**ICER - RWE for Coverage Decisions: Opportunities and Challenges** [https://icer-review.org/wp-content/uploads/2018/03/ICER-Real-World-Evidence-White-Paper-03282018.pdf](https://icer-review.org/wp-content/uploads/2018/03/ICER-Real-World-Evidence-White-Paper-03282018.pdf)  
**NICE Decision Support Unit – RWD for estimation of treatment effects** [http://nicedsu.org.uk/methods-development/real-world-data/](http://nicedsu.org.uk/methods-development/real-world-data/) | |
| **Initial HTA** | Initial HTA:  
• describe current standard of care  
• create external comparator to contextualize efficacy  
• populate cost effectiveness and budget impact models. |  | |
| **Managed entry agreement** | Managed entry agreement:  
• evaluate outcomes in clinical practice  
• resolve uncertainties related to determination of value in the initial assessment |  | |
| **Re-assessment** | Re-assessment:  
• complement the clinical and economic evidence base that was available in the initial assessment  
• monitor utilisation and evaluate budget impact in clinical practice. |  | |
| **Clinicians** | Optimal use of the technology in clinical practice  
• Monitor outcomes and adverse events to inform treatment decisions with individual patients  
• Optimize treatment regimen (dosing and who to treat)  
• Optimize therapeutic strategies (place in pathway)  
• Benchmark equity of access across health systems | Patient, rather than treatment centred approaches sharing data across Europe | **European Reference Networks** – development of disease registries for rare diseases [https://ec.europa.eu/health/sites/health/files/ern/docs/2019041052_news_en.pdf](https://ec.europa.eu/health/sites/health/files/ern/docs/2019041052_news_en.pdf) |
| Potential uses of RWE | What do we need? | Initiatives |
|----------------------|------------------|-------------|
| **Patients** | Explaining the “real-world” experience of patients  
- Evaluating unmet needs  
- Measuring patient benefit and disbenefit measuring outcomes that matter to patients | Systematic patient involvement in RWD collection  
- Responsible health data sharing that builds patients’ awareness and trust  
- Dynamic consent to give patients the power to approve use of their data on a case-by-case basis, for example using digital models of iterative opt-in/opt-out.  
- Avoidance of duplication with disease-based rather than treatment-based registries that can identify the specific patients that may be required for an HTA/regulator evaluation  
- Monitoring of inequalities to treatment access across Europe | **#DataSavesLives** initiative promotes greater awareness among patients of how health data can be used in trustworthy ways to improve health and care.  
[https://datasaveslives.eu/](https://datasaveslives.eu/)  
 **Office of Health Economics** Legal barriers to better use of health data to deliver pharmaceutical innovation.  
[https://www.ohe.org/publications/legal-barriers-better-use-health-data-deliver-pharmaceutical-innovation](https://www.ohe.org/publications/legal-barriers-better-use-health-data-deliver-pharmaceutical-innovation) |
| **Industry** | Throughout the life cycle of the technology  
- Develop understanding of therapeutic landscape and unmet needs  
- Early clinical development  
- Natural history  
- Safety  
- Clinical effectiveness  
- Economic modelling  
- Innovative pricing agreements | Overcome political, economic, societal, technical and legal barriers that hinder data collection and use  
- Investment in digital health infrastructure and harmonization across the EU  
- Alignment of RWE requirements pre- and post-licensing across HTA/payer bodies in the EU and with EMA  
- Consensus on quality and reliability of RWD sources to inform decisions  
- Adoption of new approaches to RWE generation earlier in the technology life cycle | **EFPIA oncology health data mapping**  
[https://www.efpia.eu/media/412128/efpia-oncology-data-report.pdf](https://www.efpia.eu/media/412128/efpia-oncology-data-report.pdf)  
 **imi GETReal** developing new methods for RWE collection and synthesis  
[https://www.imi-getreal.eu/](https://www.imi-getreal.eu/) |

**EFPIA European Federation of Pharmaceutical Industries and Associations; EMA European Medicines Agency; EU European Union; HMA Heads of Medicines Agencies; EUnetHTA EU network for HTA; HTA health technology assessment; ICER Institute for Clinical and Economic Review; NICE National Institute for Health and Care Excellence; RWD real-world data; RWE real-world evidence**
**RWE4Decisions – Actions for Each Stakeholder Group**

Case studies were discussed in multi-stakeholder workshops, to see if existing initiatives provided sufficient guidance to inform Payer/HTA discussions about RWD. All stakeholders agreed that the large number of initiatives showed fragmentation of approaches with divergent guidance emerging. Siloed working had led to a lack of clarity about what RWD might be suitable for what questions and how that could be developed into robust RWE to inform Payer decisions. This led to the recognition by all stakeholder groups that collaboration is essential and that this must be underpinned by trust and transparency as outlined in the vision and key principles (Figure 1). To ensure that development of RWE is seen as a shared responsibility the roles of each stakeholder to support the generation, analysis and interpretation of RWD to inform decision-making were clarified as outlined in Table 2.

**Figure 1. RWE4Decisions Vision and Principles**
Table 2. Stakeholder Roles in Relation to use of RWD in Decision-Making

| Stakeholder Group        | Role                                                                 |
|--------------------------|----------------------------------------------------------------------|
| HTA bodies/payers        | Identifying the questions that can/should be answered with RWD/RWE, providing guidance on critical assessment of RWE, collaborating with other stakeholders to collect, analyse and interpret RWD, implementing innovative payment models based requiring RWE generation |
| Regulators               | Ensuring RWD collection strategies (such as registries) are multi-stakeholder and fit for regulatory purposes and where possible take account of the needs of HTA and payers |
| Pharmaceutical Industry  | Actively engaging with other stakeholders to develop and implement plans for RWD collection, analysis and reporting over the lifecycle of a highly innovative technology to generate robust RWE that helps resolve Payer/HTA decision uncertainties |
| Registry holders¹       | Involving all stakeholders in the establishment of registries and ensuring good governance that addresses data quality, accessibility and sustainability to ensure the long-term value of registries and avoidance of waste in research |
| Clinicians and patients  | Contributing real-world experience to support collection and generation of RWD that is useful and informs decision-making at individual level, and population-level to create RWE |
| Patient groups           | As authorised representatives of patients, engaging in co-creation of RWD/RWE, communicating the possible uses of RWD and good governance processes to encourage patient involvement |
| RWD/analytics groups²    | Curation and analysis of RWD from electronic health records and other sources such as claims databases, government records etc. with a commitment to transparency, replicability and principled database epidemiology |

1. EMA uses the term ‘registry coordinator’ - a person or entity having a role in the overall coordination of a registry or of a platform of several registries. Registry holders can be patient groups, healthcare professionals, clinical institutes, manufacturers.

2. These groups could be within the health sector, academia or private sector consultancies.

Working within the principles of collaboration and transparency, each stakeholder can undertake actions to support the use of real-world evidence in Payer/HTA decisions about highly innovative technologies. Table 3 presents the recommended actions for each stakeholder group that have been modified over several iterations with the Taksforce, Review Group and public consultation, with final amendments by the authors. These recommendations are more fulsome for Payer/HTA bodies and pick up on recommendations made in ongoing initiatives by European regulators, multi-stakeholder groups.
### Table 3. RWE4Decisions Stakeholder Actions

| Payers/HTA bodies | 1. European or Multi-Country HTA or Payer Collaboratives |
|-------------------|--------------------------------------------------------|
|                   | 1.1 Collaborate with academia to better understand the potential of new statistical, econometric and modelling approaches to develop robust real-world evidence (RWE) for use in Payer/HTA decisions. |
|                   | 1.2 Encourage industry to engage in multi-stakeholder dialogues to discuss evidence generation plans including real-world data (RWD) collection. |
|                   | 1.3 Use joint processes (multi-HTA and with regulators) to document evidence gaps and key uncertainties in the clinical (and economic) evidence and identify which areas might be addressed by patient-relevant RWE. |
|                   | 1.4 Document the regulatory post-licensing evidence generation (PLEG) obligations and the additional Payer/HTA PLEG needs. Establish what PLEG is needed on national, regional, and European level. |
|                   | 1.5 For individual HTAs, agree the core dataset that is required for HTA reappraisal, within a reasonable timeframe, so that common data collection protocols can be agreed across countries and joint analyses performed. |
|                   | 1.6 Engage with the clinical community, particularly European Reference Networks (ERNs), to avoid conflicting or duplicative data collection. |
|                   | 1.7 Develop methods guides to show how RWE will be critically assessed and how the validity and applicability of RWD/RWE from another country/health setting will be determined. |
|                   | 1.8 Encourage the development of a public portal registering RWE studies that may be used in decision-making and when fully established only accept studies previously registered and reported on the portal. |

| 2. National Payers/HTA bodies | Coverage/HTA Processes |
|-------------------------------|------------------------|
| 2.1                           | Encourage establishment of national processes for data collection, analysis, critical assessment and appraisal that enable collection of relevant and reliable RWD to inform access and reimbursement decisions and optimize use of highly innovative technologies to achieve the best outcomes for patients. |
| 2.2                           | Inform national stakeholders about RWE needs for HTA and engage in developments to enable secondary use of health and social care data in the national context. |
| 2.3                           | Seek to harmonize requests to Marketing Authorization Holders for additional RWD collection with other HTA bodies and the regulator. |
| 2.4                           | Engage with stakeholders to agree responsibility for the conduct and financing of RWD collection and analysis. |
| 2.5                           | Engage with patient organizations to ensure data is collected on those outcomes that matter most to patients. |
| 2.6                           | Build capacity in data analytics and critical assessment of RWE studies. |

| Coverage/HTA Decisions for an Individual Technology |
|-----------------------------------------------------|
| 2.7 Actively explore the opportunity to use RWD from other countries/across country (e.g. European registries), preferably in collaboration with other HTA bodies, in consultation with industry, taking account of national/context specific limitations of the data. |
| 2.8 Request RWE generation plans from companies, including protocols or plans for data collection and analysis of RWE studies related to HTA. |
| 2.9 During assessment, consider the feasibility of RWD collection, possibly combined with an outcomes-based managed entry agreement (nationally or in collaboration with other countries) to manage important uncertainties and enable reassessment. |
| 2.10 When an outcomes-based managed entry agreement is used, engage with patients and clinicians to plan for potential routine adoption or modification of reimbursement conditions or disinvestment at the end of the agreement. |
Regulators
3.1 Promote use of parallel multi-HTA Scientific Advice/Early Dialogue processes including all relevant stakeholders at various points in the development of a highly innovative technology.
3.2 Develop, in co-creation with all stakeholders, guidance on generic RWE issues discussed in Scientific Advice/Early Dialogues for highly innovative technologies.
3.3 Continue to support methodological discussions with industry about non-randomized controlled trial (RCT) methodologies through methods qualification and multi-stakeholder scientific advice.
3.4 Involve HTA bodies in initiatives related to improving the quality of RWD such as registry qualification, quality standards for big data/RWD etc.
3.5 For highly innovative technologies with conditional Marketing Authorization (MA) or MA under exceptional circumstances, involve HTA bodies in discussions about requirements for post-marketing data collection.

Pharmaceutical Industry
4.1 Create a RWE generation plan early in development, which addresses essential data elements for HTA not covered in the clinical trial program and that might be studied in a real-world setting.
4.2 Discuss the RWE generation plan at various stages throughout the technology life cycle including regulators, payers, HTA bodies, clinicians and patients whenever possible.
4.3 Ensure the study (protocol) and statistical analysis plans for RWE studies that are answering major HTA questions are available to HTA bodies to provide transparency about the methods used to obtain and analyse data.
4.4 Support the development of a public portal that provides details about the design and results of major RWE studies (ala RCT registries), particularly hypothesis evaluating treatment effect studies.
4.5 Drive non-competitive, multi-company and multi-stakeholder collaborations about the development of robust RWE for diseases treated by highly innovative technologies.
4.6 Enact recommendations from the ISPOR and RWE Transparency Partnership.
4.7 Use reliable data collection methods for RWD, including ehealth and digital tools and develop best practices as digital approaches evolve.

Registry-holders
5.1 ERNs should continue to be developed and encouraged to engage with decision-makers to discuss registries and other sources of RWD.
5.2 Collaborate with regulatory authorities, HTA bodies and industry at an early stage in the development of a highly innovative technology to identify if existing registries could be used to resolve uncertainties during the development phase or for post-launch data collection, or discuss potential for new registries.
5.3 Review quality standards for registries issued by EMA and EUnetHTA and apply them.
5.4 Collaborate on an ongoing basis with HTA bodies/regulatory authorities/manufacturers to determine if a standard set of data can be collected and shared to enable pooling with other data sources for analysis.
5.5 Collaborate with European and national policy makers to develop governance structures that facilitate data quality and accessibility.
5.6 Create incentives to build and maintain disease-based, rather than product-specific, registries.
5.7 All Registries should follow the FAIR (Findable, Accessible, Interoperable, Re-usable) data principles and provide “privacy by design” – ensuring data protection through technology design.
5.8 If available in the health system, registries should use the unique patient-id to enable linkage with other health data sources.
Clinicians
6.1 ERNs and other clinical networks should systematically collaborate with regulators and Payer/HTAs when establishing their registry or other form of RWD collection to ensure it is fit for all purposes including HTA.
6.2 Enhance the H2020 EU Joint-Programme for rare diseases to include regulators and HTA bodies in order to better understand their needs.
6.3 ERNs and other clinical networks should advise on the most suitable and efficient way for health systems to collect RWD.
6.4 Encourage clinical communities to collect high quality health data (administrative, registry, audit etc) that is required for Payer/HTA decisions.
6.5 Promote the use of data driven shared decision-making processes for optimization of treatment of the individual and care pathways.
6.6 Understand the importance and relevance of the role of RWD in outcomes-based managed entry agreements in order to align on right usage and adherence to collect the data needed.

Patient Groups
7.1 Develop patient group expertise and capacity to be co-creators of RWE to ensure a holistic, patient-centred approach.
7.2 Develop EU or international patient group collaborations to engage in RWD initiatives and ensure that outcomes that matter to patients are collected.
7.3 Support the development of patient information and informed consent for RWE studies, clearly explaining study expectations (e.g. regularity of clinic visits and assessments) and treatment discontinuation rules.
7.4 Disseminate clear unbiased, patient-relevant information about RWD and RWE to patient communities, including the value of secondary use of data.
7.5 Provide recommendations on novel and efficient collection methods for RWD (e.g. devices, wearables, mHealth).
7.6 Help promote the scientific and policy value of data collection and provide access within strict governance frameworks ensuring appropriate confidentiality, e.g. via the #DataSavesLives initiative.
7.7 Work with stakeholders to encourage alignment of views on identification, collection, analysis and evaluation of RWD for decision-making.

RWD/analytics groups
8.1 Engage with HTA bodies and other stakeholders in demonstration projects related to highly innovative technologies.
8.2 Collaborate with industry and HTA bodies to generate RWE for outcomes-based Managed Entry Agreements (MEA).
8.3 Contribute to research collaborations that lead to published guidance on the use of RWD for specific research questions relevant to HTA of highly innovative technologies.
8.4 Work with stakeholders to develop reporting standards, including full transparency, software audit trails and study pre-registration.
8.5 Collaborate with industry, regulators and HTA bodies to enhance the efficiency of preparation and submission of RWE that facilitates transparency, addresses proprietary data and privacy challenges and includes robust data governance.
8.6 Work with stakeholders to develop criteria to evaluate RWD’s fitness for purpose, provenance, transparency and adherence to governance standards in order to inform the evaluation of RWE.
8.7 Publish analytical methods to generate reliable RWE for HTA.

ERNs, European Reference Networks; FAIR, Findable Accessible Interoperable Re-usable; MA, Marketing Authorization; MEA, Managed Entry Agreement; PLEG, Post-Licensing Evidence Generation; RCT, Randomized Controlled Trials; RWD, Real-World Data; RWE, Real-World Evidence;
Discussion

In this initiative, case studies of recent Payer/HTA assessments about highly innovative technologies were considered against recent policy proposals relating to RWD. This showed a lack of clarity about the Payer/HTA questions that could be answered by RWD and how the quality of real-world evidence (RWE) could be assessed. All stakeholders worked together to create a vision whereby stakeholders agree what RWD can be collected for highly innovative technologies based on principles of collaboration and transparency. For each stakeholder group, recommended actions to support the generation, analysis and interpretation of RWD to inform decision-making were developed.

At the outset of this work, the intention was to provide a one-page quick reference guide highlighting key actions that could be taken to develop RWE for highly innovative technologies. After the case studies, actions needed by HTA/Payers, regulatory bodies and industry were proposed. In this activity individuals identified that patient groups, registry holders and clinicians should also take responsibility for certain actions and so they were developed. In consultation, it became apparent that the stakeholder group of RWD/analytics organisations was missing. Actions were developed for this group based on the comments of the consultee and consulted upon with another analytics organisation and the Taskforce. Hence rather than a one-pager, a list of actions was created for each stakeholder group. This is important because central to the RWE4Decisions vision is that development of robust RWE is a shared responsibility.

In Europe, collaboration across Members States is also essential, particular for very rare diseases, where study in one country will be insufficient.

The EU’s new data strategy (10) promotes data-driven innovation to bring major benefits to citizens. Health is acknowledged as one of the sectors where Europe can benefit from the data revolution: improving the quality of healthcare, whilst decreasing costs, but this requires the right governance mechanisms to be put in place. To enable this, the European Commission (EC) will propose legislative or non-legislative measures for development of a European Health Data Space to promote health data exchange and support better diagnosis, care and outcomes for patients. It is an essential step for informed, evidence-based decisions to improve the accessibility, effectiveness and sustainability of the healthcare systems (11).

In the EU, Public-Private partnerships, like the IMI Big Data for Better Outcomes projects provide important test beds for collation of data in a particular medical field and proof of concept for how data can be effectively shared to answer clinical questions. The GetReal Initiative has focused on methods development for RWD to inform both regulatory and HTA decision-making and is seeking a sustainable platform.

RWE4Decisions has focussed on the EU given the imperative for cross border collaboration, but internationally other RWD initiatives are emerging that will be important to link with.

The US FDA's Sentinel program, involving over 100 million individuals, is a trusted source for pharmacovigilance. Building on that experience the FDA has created a RWE Program that will provide guidance on the relevance and reliability of RWD and the design and analysis of effectiveness studies to inform regulatory decisions. This will include demonstration projects and involve the FDA leadership to promote shared learnings and consistency of approaches across the Agency (7).

The World Health Organization has stated that digital health initiatives need to be underpinned by a robust strategy that integrates financial, organizational, human and technological resources (8), recognizing legal constraints and national contexts. Ideally, a legal framework, platform and governance processes are needed that provide access to health data across
Europe via appropriate governance mechanisms for bona fide research and decision-making purposes, taking into consideration public concerns about commercialisation of patient and health system data. We are some distance away from that vision, but areas of progress are seen. The eHealth Digital Service Infrastructure enables sharing of prescription data and patient summaries between MS (11). Although only a small number of countries are currently involved, contribution and experience is building that will enhance future learning and collaboration.

Essential to the RWE4Decision vision is that there is transparency in RWE generation. This is not simple given the need to maintain a competitive advantage that is obvious in any industry. However, the ISPOR RWE transparency taskforce is tackling this issue and will produce important findings agreed by all stakeholders in the future.

In 2019, the HTAi Global Policy Forum noted that despite the promise of RWD, the HTA community is not yet fully equipped to address the challenges of using RWD (17). They called for more clarity on methods, standards, streamlined collection of RWD, data sharing across jurisdictions, replication of RWD and expert analysis. It suggested that the HTA community should develop actions and guidance to develop and manage RWD/RWE to inform decision-making. This paper seeks to respond to that by choosing a challenging area for Payers/HTA that could be informed by RWE and proposing actions for each stakeholder group. But this is not enough. We need to embody continuous improvement cycles, reflecting on attempted actions, modifying them with experience. As a result, INAMI is undertaking meetings to provide informal advice on highly innovative technologies that are in development, taking account of the stakeholder actions, seeking to develop general learnings that can be shared. Other stakeholders are socializing RWE4Decisions in their networks and seeking link implementation with other initiatives such as #DataSavesLives.

**A Multi-Stakeholder EU Learning Network on RWE**

The Heads of Medicines Agency (HMA) and EMA have indicated that to develop use of Big Data in health, iterative approaches are needed with relevant stakeholders. This should support data standardization and improved data quality, promotion of data sharing and access, then robust data processing and analyses may be possible to produce RWE that has regulatory acceptability (22). To develop this work, they have issued ten recommendations that include delivery of a sustainable platform to access and analyse healthcare data from across the EU (DARWIN) (13). This is essential to enable cross border data sharing. An EU Big Data “stakeholder implementation forum” is also proposed to build a resource of key messages and communication materials on regulation and Big Data. The RWE4Decisions initiative is keen to see the development of this forum and following the multi-stakeholder work of INAMI over recent years, it is hoped that it will follow the ‘Bad Gastein’ principle in terms of breadth of participation to be collaborative “Learning Network”. This could use the EC’s Open Innovation 2.0 approach (23, 24), where all stakeholders work together to enable cross-fertilization of ideas to develop innovation far beyond the scope of what one organization or initiative can do alone. Järvensivu (25) provides guidance on learning, working and leading together in networks, which we have used to develop principles for a Learning Network as outlined in Box 1.

The RWE4Decisions initiative can do its part in a multi-stakeholder EU Learning Network for RWE by continuing to bring together policy makers, payers, HTA bodies, regulatory bodies, clinicians, patient groups, industry and academic experts to share expertise as they try to implement these stakeholder actions. Keeping abreast of initiatives in other groups, piloting new processes with decision makers, discussing implementation challenges and reflecting on challenges and successes can all contribute to outputs and continuous learning to realise improvements in the use of RWE to inform decisions about highly innovative technologies.
This is particularly important for areas where there is high unmet need and where EU cross border collaboration is most needed, in the area of rare diseases.

**Box 1. Developing an Effective Learning Network**

**Key principles**
A Learning Network needs to:
- ✓ be premised on open governance, reciprocity and legitimacy through comprehensive membership
- ✓ enable knowledge sharing and dialogue, and operate on the basis of shared responsibilities and clear roles
- ✓ be able to develop actions, to reach goals efficiently, and be able to question goals and practices to develop new learning methods
- ✓ enable the attainment of common goals, develop network members’ own work, skill and capabilities

**In order to deliver on the goals, the Learning Network must be:**
- Owned by a public institution
- Enabling the multi-stakeholder interaction
- Sustainable through long-term funding.

**Conclusions**

Highly innovative technologies make a good case study to consider how RWE can be developed through iterative multi-stakeholder dialogues to inform decisions by Payers/HTA bodies. All stakeholders need to be involved, to agree what RWD is needed for what purpose, how it can be collected, when, by whom and how. This includes considerations of cross-border (cross-health system) HTA/regulatory collaboration to agree RWD requirements and the associated infrastructure, development of data analytics methods for HTA and transparency in RWE studies akin to that of RCTs. Demonstration projects on highly innovative technologies could realise some of the stakeholder actions presented in this paper, start to deliver some of the outputs and inform how new processes can be developed. This will provide substantial insights to a wider learning network that could develop systems to support a learning health system, optimization of health technology use and improvement in patient outcomes through best use of RWD.
References

1. Alliance for Regenerative Medicine. [Internet] Getting ready: recommendations for timely access to Advanced Therapy Medicinal Products (ATMPs) in Europe 2019. July 2019. [cited 2020 Mar 4]. Available from: http://alliancerm.org/wp-content/uploads/2019/07/ARM-Market-Access-Report-FINAL.pdf

2. Alliance for Regenerative Medicine. [Internet] Global sector report – regenerative medicine and rare disease 2019. [cited 2020 Mar 4]. Available from: https://alliancerm.org/indication data/rare-disease-2019.pdf

3. INAMI/RIZIV Annemans L. [Internet] The use of real world data throughout an innovative medicine’s lifecycle. 2016 [cited 2020 Mar 3]. Available from: https://www.inami.fgov.be/SiteCollectionDocuments/real_world_data.docx

4. OECD. [Internet] Using routinely collected data to inform pharmaceutical policies: Analytical Report. February 2019 [cited 2020 Mar 10]. Available from: https://www.oecd.org/els/health-systems/routinely-collected-data-to-inform-pharmaceutical-policies.htm

5. Swift B, Jain L, White C, Chandrasekaran V, Bhandari A, Hughes DA et al. Innovation at the Intersection of Clinical Trials and Real-World Data Science to Advance Patient Care. Clin Transl Sci. 2018;11:450-460.

6. Plueschke K, McGettigan P, Pacurariu A, Kurz X, Cave A. EU-funded initiatives for real world evidence: descriptive analysis of their characteristics and relevance for regulatory decision-making. BMJ Open. 2018;8:e021864

7. US Food & Drug Administration (FDA). [Internet] Framework for FDA’s Real-World Evidence Program. December 2018. [cited 2020 Mar 4] Available from: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence

8. World Health Organization (WHO) [Internet] Global Strategy on Digital Health 2020-2024. Draft 25th February 2020 [cited 2020 Mar 7]. Available from: https://www.who.int/docs/default-source/documents/gs4dhdda2a9f352b0445bafbc79ca799dce4d.pdf?sfvrsn=f112ede5_28

9. The Learning Healthcare Project. [Internet] Background – Learning Healthcare System. [cited 2020 Mar 7]. Available from: http://www.learninghealthcareproject.org/section/background/learning-healthcare-system

10. European Commission. [Internet]. A European strategy for data. Brussels, 19.2.2020. COM(2020); 66 final: p23, 30-31, [cited 2020 Mar 11]. Available from: https://ec.europa.eu/info/sites/info/files/communication-european-strategy-data-19feb2020_en.pdf

11. European Commission. [Internet] A European strategy for data. Brussels, 19.2.2020. COM(2020); 66 final: p23, 30-31, [cited 2020 Mar 11]. Available from: https://ec.europa.eu/info/sites/info/files/communication-european-strategy-data-19feb2020_en.pdf

12. Cave A, Kurz X, Arlett P. Real-World Data for Regulatory Decision-Making: Challenges and Possible Solutions for Europe. Clin Pharmacol Ther. 2019;106:36-39.

13. Heads of Medicines Agencies – European Medicines Agency [Internet] HMA-EMA Joint Big Data Taskforce Phase II report: ‘Evolving Data-Driven Regulation’. EMA/584203/2019 [cited 2020 Mar 10]. Available from: https://www.ema.europa.eu/en/documents/other/hma-ema-joint-big-data-taskforce-phase-ii-report-evolving-data-driven-regulation_en.pdf
14. TLV. [Internet] Follow-up of drug utilisation and treatment effects in clinical practice. Stockholm: Dental and Pharmaceutical Benefits Agency, 25/01/2019. [cited 2020 March 10]. Available from: https://www.tlv.se/download/18.24b9c52f16cc59e80009df2f/1567172243382/rapport_follow_up_of_drug_utilisation_and_treatment_effects%20in_clinical_practice.pdf

15. National Institute for Health and Care Excellence (NICE) [Internet] Widening the evidence base: use of broader data and applied analytics in NICE's work. [cited 2020 Mar 3]. Available from: https://heatinformatics.com/posts/widening-evidence-base

16. Pearson SD, Dreitlein WB, Towse, A, Hampson G, Henshall C. A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions. J Comp Effect Res. 2018;7:1145-1152.

17. Oortwijn W, Sampietro-Colom L, Trowman R. How to deal with the inevitable: generating real-world data and using real-world evidence for HTA purposes – from theory to action. Int J Tech Assess Health Care. 2019;35:346-350.

18. INAMI/RIZIV Annemans L, Pani L. [Internet] Outcomes-based pricing and reimbursement of innovative medicines with budgetary limitations. Discussion document for the multi-stakeholder meeting on pharmaceuticals. 2017 [cited 2020 Mar 4]. Available from: https://www.inami.fgov.be/SiteCollectionDocuments/innovative_medicines_with_budgetary_limitations.docx

19. Annemans L, Makady A. TRUST4RD - Tool to Reduce the Uncertainties in the evidence generation for Specialised Treatments for Rare Diseases. Submitted to Orphanet. 2019.

20. World Economic Forum. [Internet]. Federated data systems: balancing innovation and trust in the use of sensitive data. July 2019. [cited 2020 March 10]. Available from: http://www3.weforum.org/docs/WEF_Federated_Data_Systems_2019.pdf

21. European Health Forum Gastein. [Internet] History, Objectives and Goals. [cited 2020 Mar 7]. Available from: https://www.ehfg.org/about-us/ehfg/

22. Heads of Medicines Agencies – European Medicines Agency. [Internet] HMA-EMA Joint Big Data Taskforce Summary Report. February 2019 [cited 2020 Mar 10]. Available from: https://www.ema.europa.eu/documents/minutes/ema/joint-task-force-big-data-summary-report_en.pdf

23. Curley M, Salmelin, B. Open Innovation 2.0 – The New Mode of Digital Innovation for Prosperity and Sustainability. Singapore: Springer; 2018.

24. Von Schomberg R, Hankins J, editors. International Handbook on Responsible Innovation. Cheltenham: Edward Elgar Publishing; 2019. https://doi.org/10.4337/9781784718862

25. Järvensivu T. Managing (in) networks – Learning, working and leading together. Helsinki: Books on Demand; 2020.